Grifols (GRFS) P/B (2011 - 2026)
Grifols (GRFS) P/B from Jun 2, 2011 to Jul 21, 2026. The TTM Grifols (GRFS) P/B is 0.84. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/B
Annual P/B change of Grifols (GRFS)
| Year | P/B | Change |
|---|---|---|
| 2026 | 0.84 | -18.73% |
| 2025 | 1.03 | +23.73% |
| 2024 | 0.83 | -31.98% |
| 2023 | 1.22 | -92.20% |
| 2022 | 15.66 | +1196.65% |
| 2021 | 1.21 | -40.18% |
| 2020 | 2.02 | -20.70% |
| 2019 | 2.55 | -1.76% |
| 2018 | 2.59 | -30.57% |
| 2017 | 3.73 | +36.61% |
| 2016 | 2.73 | -11.64% |
| 2015 | 3.09 | -15.41% |
| 2014 | 3.66 | -13.25% |
| 2013 | 4.22 | +20.07% |
| 2012 | 3.51 | +121.24% |
| 2011 | 1.59 | N/A |
Comparison Grifols (GRFS) P/B with competitors
Grifols (GRFS) P/B is 0.84.
| Ticker | Name | P/B | Upside |
|---|---|---|---|
| AMRN | Amarin Corp | 0.68 | -18.15% |
| SNY | Sanofi | 1.27 | +51.97% |
| BIIB | Biogen Inc | 1.52 | +81.77% |
| PFE | Pfizer Inc | 1.55 | +85.24% |
| OGN | Organon & Company | 3.93 | +369.80% |
| MIRA | Mira Pharmaceuticals Inc | 4.09 | +389.55% |
| GSK | GSK Plc | 4.37 | +423.17% |
| BMY | Bristol-Myers Squibb Company | 6.04 | +622.77% |
| AZN | Astrazeneca plc | 6.20 | +641.92% |
| MRK | Merck & Co Inc | 6.68 | +699.36% |
| GILD | Gilead Sciences Inc | 6.94 | +730.47% |
| NVO | Novo Nordisk | 7.07 | +746.03% |
| NVS | Novartis AG | 7.60 | +809.45% |
| JNJ | Johnson & Johnson | 7.64 | +814.24% |
| NSRX | Nasus Pharma Ltd | 12.90 | +1443.67% |
| MDCX | MDCorp | 15.34 | +1735.65% |
| AMGN | AMGEN Inc | 21.17 | +2433.30% |
| SCLX | Scilex Holding Company | 28.85 | +3352.32% |
| LLY | Lilly(Eli) & Company | 32.94 | +3841.75% |
| ABBV | Abbvie Inc | 50.46 | +5938.27% |